Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition

The US FDA approval of broad-spectrum histone deacetylase (HDAC) inhibitors has firmly laid the cancer community to explore HDAC inhibition as a therapeutic approach for cancer treatment. Hitting one HDAC member could yield clinical benefit but this required a complete understanding of the functions of the different HDAC members. Here we explored the consequences of specific HDAC5 inhibition in cancer cells. We demonstrated that HDAC5 inhibition induces an iron-dependent reactive oxygen species (ROS) production, ultimately leading to apoptotic cell death as well as mechanisms of mitochondria quality control (mitophagy and mitobiogenesis). Interestingly, adaptation of HDAC5-depleted cells to oxidative stress passes through reprogramming of metabolic pathways towards glucose and glutamine. Therefore, interference with both glucose and glutamine supply in HDAC5-inhibited cancer cells significantly increases apoptotic cell death and reduces tumour growth in vivo; providing insight into a valuable clinical strategy combining the selective inhibition of HDAC5 with various inhibitors of metabolism as a new therapy to kill cancer cells.

[1]  S. Shah,et al.  In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. , 1998, Kidney international.

[2]  E. Olson,et al.  Histone Deacetylases 5 and 9 Govern Responsiveness of the Heart to a Subset of Stress Signals and Play Redundant Roles in Heart Development , 2004, Molecular and Cellular Biology.

[3]  M. Lamy,et al.  Resveratrol and curcumin reduce the respiratory burst of Chlamydia-primed THP-1 cells. , 2005, Biochemical and biophysical research communications.

[4]  M. Smith,et al.  Causes of oxidative stress in Alzheimer disease , 2007, Cellular and Molecular Life Sciences.

[5]  DenisMottet,et al.  Histone Deacetylase 7 Silencing Alters Endothelial Cell Migration, a Key Step in Angiogenesis , 2007 .

[6]  D. Mottet,et al.  Histone deacetylases: target enzymes for cancer therapy , 2007, Clinical & Experimental Metastasis.

[7]  M. Muckenthaler,et al.  Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. , 2009, Journal of Alzheimer's disease : JAD.

[8]  V. Castronovo,et al.  HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism , 2009, Oncogene.

[9]  Florian Diehl,et al.  HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. , 2009, Blood.

[10]  M. L. Genova,et al.  Mitochondrial respiratory chain super-complex I-III in physiology and pathology. , 2010, Biochimica et biophysica acta.

[11]  O. Kovalchuk,et al.  Role of ferritin alterations in human breast cancer cells , 2011, Breast Cancer Research and Treatment.

[12]  P. Riederer,et al.  The link between iron, metabolic syndrome, and Alzheimer’s disease , 2011, Journal of Neural Transmission.

[13]  F. Chantraine,et al.  Thiamine Status in Humans and Content of Phosphorylated Thiamine Derivatives in Biopsies and Cultured Cells , 2010, PloS one.

[14]  Shengbing Huang,et al.  The Role of Autophagy in Cancer: Therapeutic Implications , 2011, Molecular Cancer Therapeutics.

[15]  T. Saigusa,et al.  Mitophagy Plays an Essential Role in Reducing Mitochondrial Production of Reactive Oxygen Species and Mutation of Mitochondrial DNA by Maintaining Mitochondrial Quantity and Quality in Yeast* , 2011, The Journal of Biological Chemistry.

[16]  P. Munster,et al.  Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. , 2011, Future oncology.

[17]  M. Harper,et al.  Uncoupling proteins and the control of mitochondrial reactive oxygen species production. , 2011, Free radical biology & medicine.

[18]  T. Copetti,et al.  Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review , 2011, Front. Pharmacol..

[19]  M. Duvic,et al.  HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. , 2012, Future medicinal chemistry.

[20]  P. Marks,et al.  Curbing autophagy and histone deacetylases to kill cancer cells , 2012, Autophagy.

[21]  Lucia Altucci,et al.  Trials with ‘epigenetic’ drugs: An update , 2012, Molecular oncology.

[22]  Denis Mottet,et al.  HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells , 2012, Cell Death and Differentiation.

[23]  O. Margalit,et al.  Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function , 2012, International journal of cancer.

[24]  A. Fischer,et al.  Loss of HDAC5 impairs memory function: implications for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[25]  I. Pogribny,et al.  Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. , 2013, International journal of oncology.

[26]  Tongshan Wang,et al.  Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. , 2013, Future oncology.

[27]  Sung Soo Kim,et al.  Cancer cell metabolism: implications for therapeutic targets , 2013, Experimental & Molecular Medicine.

[28]  A. Mouithys-Mickalad,et al.  Effect of myeloperoxidase and anoxia/reoxygenation on mitochondrial respiratory function of cultured primary equine skeletal myoblasts. , 2013, Mitochondrion.

[29]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[30]  E. Aizenman,et al.  The role of intracellular zinc release in aging, oxidative stress, and Alzheimer’s disease , 2014, Front. Aging Neurosci..

[31]  M. Bianchini,et al.  Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy , 2014, Molecular Cancer Therapeutics.

[32]  Quan Liu,et al.  Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1. , 2014, Molecular medicine reports.

[33]  A. Jimeno,et al.  Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. , 2014, Drugs of today.

[34]  A. Shah,et al.  Redox regulation of cardiac hypertrophy. , 2014, Journal of molecular and cellular cardiology.

[35]  G. Mazzucchelli,et al.  Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. , 2014, Cell metabolism.

[36]  Christian Frezza,et al.  Defects in mitochondrial metabolism and cancer , 2014, Cancer & metabolism.

[37]  A. Jimeno,et al.  Belinostat for the treatment of peripheral T-cell lymphomas. , 2014, Drugs of today.

[38]  Wei Chen,et al.  Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest , 2014, Tumor Biology.

[39]  P. He,et al.  HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression. , 2015, International journal of clinical and experimental medicine.

[40]  T. Cheng,et al.  Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma. , 2015, Drugs of today.

[41]  Qifu Li,et al.  Redox signaling: Potential arbitrator of autophagy and apoptosis in therapeutic response. , 2015, Free radical biology & medicine.

[42]  I. Harris,et al.  Cancer: The enemy of my enemy is my friend , 2015, Nature.

[43]  O. O’Connor,et al.  Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review , 2015, Therapeutic advances in hematology.

[44]  J. Connor,et al.  Cytoprotective effects of ferritin on doxorubicin-induced breast cancer cell death , 2015, Oncology reports.

[45]  R. Houtkooper,et al.  Mitochondrial quality control pathways as determinants of metabolic health , 2015, BioEssays : news and reviews in molecular, cellular and developmental biology.

[46]  Boris Ratnikov,et al.  Glutamate and asparagine cataplerosis underlie glutamine addiction in melanoma , 2015, Oncotarget.

[47]  D. Butterfield,et al.  Strategy to reduce free radical species in Alzheimer’s disease: an update of selected antioxidants , 2015, Expert review of neurotherapeutics.

[48]  Jianying Gu,et al.  Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells , 2016, Journal of Translational Medicine.

[49]  D. Sabatini,et al.  An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis , 2015, Cell.

[50]  D. A. Foster,et al.  Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells* , 2016, The Journal of Biological Chemistry.

[51]  Yaguang Si,et al.  Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. , 2016, Cell reports.

[52]  M. Werner,et al.  Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity , 2016, Laboratory Investigation.

[53]  Xinyang Zhang,et al.  Enhanced Cisplatin Chemotherapy by Iron Oxide Nanocarrier-Mediated Generation of Highly Toxic Reactive Oxygen Species. , 2017, Nano letters.